Literature DB >> 29031202

Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells.

Xiaoxu Li1, Ruiyu Ding2, Zewen Han3, Zeyun Ma4, Yixiang Wang5.   

Abstract

The low median survival rate of oral squamous cell carcinoma (OSCC) is associated with chemotherapeutic resistance. Niclosamide is an oral anti-helminthic drug, its anti-cancer effect has been reported in recent years. However, the effect of niclosamide on OSCC remains largely unknown. In this study, we, for the first time, investigated the underlying mechanisms from cell cycle arrest and let-7a/STAT3 axis through CCK-8, cell cycle, apoptosis, wound healing, Transwell invasion, generation of stable cell line, real-time PCR, and western blot assays using two OSCC cell lines WSU-HN6 and Tca83. We showed that niclosamide could inhibit OSCC cells proliferation through causing cell cycle arrest in G1 phase and promoting apoptosis, while the cell cycle-related proteins MCM2, MCM7, CDK2 and CDK4 were downregulated and the apoptosis-related proteins p53 and cleaved caspase-3 were upregulated. Furthermore, niclosamide could inhibit migration and invasion of OSCC through upregulation of let-7a expression and downregulation of p-STAT3 expression. What is more, we established the stably expressing let-7a cell line (HN6-let-7a). Like niclosamide, HN6-let-7a could decrease the ability of the cell migration, invasion as well as the expression of p-STAT3. Collectively, our study finds the new mechanisms that niclosamide inhibits OSCC proliferation through causing cell cycle arrest in G1 phase via downregulation of the above cell cycle-related genes; promotes OSCC apoptosis through upregulation of pro-apoptotic genes; decreases migration and invasion of OSCC by let-7a/STAT3 axis, thus providing a preferred therapeutic candidate for OSCC in future.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cell cycle; Invasion; Migration; Niclosamide; Oral squamous cell carcinoma; Proliferation; STAT3; let-7a

Mesh:

Substances:

Year:  2017        PMID: 29031202     DOI: 10.1016/j.biopha.2017.09.149

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  14 in total

Review 1.  The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Authors:  Elina Khatoon; Mangala Hegde; Aviral Kumar; Uzini Devi Daimary; Gautam Sethi; Anupam Bishyaee; Ajaikumar B Kunnumakkara
Journal:  Arch Pharm Res       Date:  2022-08-20       Impact factor: 6.010

2.  A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway.

Authors:  Chia-Lun Wu; Chun-Liang Chen; Hsu-Shan Huang; Dah-Shyong Yu
Journal:  Cancer Med       Date:  2018-06-28       Impact factor: 4.452

3.  MicroRNAs alteration as early biomarkers for cancer and neurodegenerative diseases: New challenges in pesticides exposure.

Authors:  Chiara Costa; Michele Teodoro; Carmela Alessandra Rugolo; Carmela Alibrando; Federica Giambò; Giusi Briguglio; Concettina Fenga
Journal:  Toxicol Rep       Date:  2020-05-21

4.  Let-7a inhibits osteosarcoma cell growth and lung metastasis by targeting Aurora-B.

Authors:  Jing-Jing Yu; Wen-Sen Pi; Yuan Cao; Ai-Fen Peng; Zhi-Yuan Cao; Jia-Ming Liu; Shan-Hu Huang; Zhi-Li Liu; Wei Zhang
Journal:  Cancer Manag Res       Date:  2018-11-26       Impact factor: 3.989

5.  Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.

Authors:  Jia Wang; Jie Zuo; Alafate Wahafu; Mao-de Wang; Rui-Chun Li; Wan-Fu Xie
Journal:  CNS Neurosci Ther       Date:  2019-07-18       Impact factor: 5.243

6.  Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma.

Authors:  Yue Zhao; Dongsheng Bai; Jiaying Du; Haochuan Ren; Zhenguo Zhang; Cheng Jiang; Na Lu
Journal:  Cell Biol Toxicol       Date:  2020-10-30       Impact factor: 6.691

7.  Bupivacaine inhibits the malignant biological behavior of oral squamous cell carcinoma cells by inhibiting the activation of ERK1/2 and STAT3.

Authors:  Zhongchao Wang; Jie Zhang; Yongmei Wen; Pin Wang; Liyuan Fan
Journal:  Ann Transl Med       Date:  2021-05

8.  Decreased TMEM40 expression is associated with malignant behavior of cutaneous squamous cell carcinoma and inhibits tumor progression.

Authors:  Lei Yu; Jie Liu; Tang-De Zhang; Xiu-Fen Zheng; Dong-Lan Luo; Wei-Liang Zhu; Xian-Wen Qiu; Lin-Lang Guo
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

9.  Niclosamide Induces Cell Cycle Arrest in G1 Phase in Head and Neck Squamous Cell Carcinoma Through Let-7d/CDC34 Axis.

Authors:  Zewen Han; Qingxiang Li; Yifei Wang; Lin Wang; Xiaoxu Li; Na Ge; Yixiang Wang; Chuanbin Guo
Journal:  Front Pharmacol       Date:  2019-01-09       Impact factor: 5.810

10.  Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.

Authors:  Ming-Cheng Lee; Yin-Kai Chen; Yih-Jen Hsu; Bor-Ru Lin
Journal:  Oncol Rep       Date:  2019-12-27       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.